CHF47.65
0.74% day before yesterday
SIX Swiss Exchange, Apr 25, 05:31 pm CET
ISIN
NL0011832936
Symbol
COPN
Sector
Industry

COSMO Pharmaceuticals Target price 2025 - Analyst rating & recommendation

COSMO Pharmaceuticals Classifications & Recommendation:

Buy
100%

COSMO Pharmaceuticals Price Target

Target Price CHF85.37
Price CHF47.65
Potential
Number of Estimates 2
2 Analysts have issued a price target COSMO Pharmaceuticals 2026 . The average COSMO Pharmaceuticals target price is CHF85.37. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 2 Analysts recommend COSMO Pharmaceuticals to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the COSMO Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the COSMO Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 254.14 158.69
181.94% 37.56%
EBITDA Margin 59.04% 57.17%
579.66% 3.16%
Net Margin 48.92% 2.14%
523.44% 95.63%

2 Analysts have issued a sales forecast COSMO Pharmaceuticals 2025 . The average COSMO Pharmaceuticals sales estimate is

CHF159m
Unlock
. This is
37.58% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF221m 12.89%
Unlock
, the lowest is
CHF95.9m 62.26%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF254m 181.94%
2025
CHF159m 37.56%
Unlock
2026
CHF125m 21.48%
Unlock
2027
CHF135m 8.03%
Unlock

2 Analysts have issued an COSMO Pharmaceuticals EBITDA forecast 2025. The average COSMO Pharmaceuticals EBITDA estimate is

CHF90.7m
Unlock
. This is
39.64% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF143m 5.13%
Unlock
, the lowest is
CHF38.8m 74.16%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF150m 1,816.22%
2025
CHF90.7m 39.53%
Unlock
2026
CHF52.5m 42.08%
Unlock
2027
CHF95.2m 81.17%
Unlock

EBITDA Margin

2024 59.04% 579.66%
2025
57.17% 3.16%
Unlock
2026
42.17% 26.24%
Unlock
2027
70.71% 67.68%
Unlock

1 Analyst has issued a net profit forecast COSMO Pharmaceuticals 2025 . The average COSMO Pharmaceuticals net profit estimate is

CHF3.4m
Unlock
. This is
97.32% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF3.4m 97.32%
Unlock
, the lowest is
CHF3.4m 97.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF124m 1,293.85%
2025
CHF3.4m 97.27%
Unlock
2026
CHF16.6m 390.86%
Unlock
2027
CHF45.1m 171.21%
Unlock

Net Margin

2024 48.92% 523.44%
2025
2.14% 95.63%
Unlock
2026
13.35% 523.83%
Unlock
2027
33.53% 151.16%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 7.76 0.21
1,293.85% 97.29%
P/E 225.25
EV/Sales 4.02

1 Analysts have issued a COSMO Pharmaceuticals forecast for earnings per share. The average COSMO Pharmaceuticals EPS is

CHF0.21
Unlock
. This is
97.35% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF0.21 97.35%
Unlock
, the lowest is
CHF0.21 97.35%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF7.76 1,293.85%
2025
CHF0.21 97.29%
Unlock
2026
CHF1.04 395.24%
Unlock
2027
CHF2.82 171.15%
Unlock

P/E ratio

Current 6.02 102.46%
2025
225.25 3,641.69%
Unlock
2026
45.88 79.63%
Unlock
2027
16.91 63.14%
Unlock

Based on analysts' sales estimates for 2025, the COSMO Pharmaceuticals stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.51
2025
4.02 60.02%
Unlock
2026
5.11 27.35%
Unlock
2027
4.73 7.43%
Unlock

P/S ratio

Current
2025
4.81 60.20%
Unlock
2026
6.12 27.35%
Unlock
2027
5.67 7.43%
Unlock

Current COSMO Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Mar 31 2025
ODDO BHF
Locked
Locked
Locked Mar 06 2025
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked Jan 09 2025
BERENBERG
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
ODDO BHF:
Locked
Locked
Mar 06 2025
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
Jan 09 2025
Locked
BERENBERG:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today